| Role of alendronate and risedronate in preventing and treating osteoporosis. | |
| | |
MedLine Citation:
|
PMID: 11718433 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Alendronate and risedronate, the two oral bisphosphonates approved in the United States for preventing and treating osteoporosis, have never been compared in direct head-to-head trials, but they appear to have similar pharmacokinetics, drug interactions, adverse effect profiles, and efficacy. Alendronate, however, can be given as a once-weekly dose, whereas risedronate is not yet available in this dosage form. On the other hand, alendronate is not approved for preventing glucocorticoid-induced osteoporosis, whereas risedronate carries this indication. |
| | |
Authors:
|
M L Peters; M Leonard; A A Licata |
Related Documents
:
|
18446503 - Informatic tools and approaches in postmarketing pharmacovigilance used by fda. 10177333 - Medical devices; exemptions from premarket notification and reserved devices; class i--... 16637793 - Potential interactions between prescription drugs and complementary and alternative med... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Cleveland Clinic journal of medicine Volume: 68 ISSN: 0891-1150 ISO Abbreviation: Cleve Clin J Med Publication Date: 2001 Nov |
Date Detail:
|
Created Date: 2001-11-22 Completed Date: 2001-12-12 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8703441 Medline TA: Cleve Clin J Med Country: United States |
Other Details:
|
Languages: eng Pagination: 945-51 Citation Subset: IM |
Affiliation:
|
Department of Pharmacy, The Cleveland Clinic Foundation, OH 44195, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alendronate
/
administration & dosage,
adverse effects,
therapeutic use* Cost-Benefit Analysis Diphosphonates / therapeutic use Dose-Response Relationship, Drug Etidronic Acid / administration & dosage, adverse effects, analogs & derivatives*, therapeutic use* Female Humans Male Osteoporosis / chemically induced, drug therapy* Osteoporosis, Postmenopausal / drug therapy Practice Guidelines as Topic United States |
| Chemical | |
Reg. No./Substance:
|
0/Diphosphonates; 105462-24-6/risedronic acid; 2809-21-4/Etidronic Acid; 66376-36-1/Alendronate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Chronic myelogenous leukemia: the news you have and haven't heard.
Next Document: Prevention for positives: challenges and opportunities for integrating prevention into HIV case mana...